Biopharmaceutical Cell Culture Market

Market Snapshot

• The Global Biopharmaceutical Cell Culture Market is valued at USD 13.28 Billion in 2025, expected to reach USD 15.70 Billion in 2026 and is forecast to reach USD 67.12 Billion by 2035, expanding at a CAGR of 16.9%.
• The US market stands at USD 7.13 Billion in 2025, projected to reach USD 29.19 Billion by 2035, growing at a CAGR of 15.3%.
• The China market is valued at USD 6.63 Billion in 2025, forecast to reach USD 28.26 Billion by 2035, at a CAGR of 15.9%.
• By Product, Consumables hold the largest share at 73.6% of total revenue in 2025.
• By Application, Biopharmaceutical Production leads with the highest CAGR of 12.3%.
• By Type, Monoclonal Antibodies (mAbs) hold the largest share in 2025.
• By End-User, Pharmaceutical and Biotechnology Companies hold the largest share in 2025.
• By Technology, 2D Cell Culture holds the largest share; 3D Cell Culture is the key emerging segment.
• By Raw Material, Media dominates within the Consumables segment.
• By 3D Cell Culture Technology, Scaffold-based systems hold 46.43% revenue share.
• North America leads all regions with 39.8% revenue share, with the US accounting for 87.8% of that regional total.
• Key players include Thermo Fisher Scientific, Danaher Corporation, Sartorius AG, Merck KGaA, Corning Incorporated, Lonza Group, and others.

Market Overview

Global Biopharmaceutical Cell Culture Market size is expected to be worth around USD 62.37 Billion by 2035 from USD 15.52 Billion in 2026, growing at a CAGR of 16.9% during the forecast period 2026 to 2035.. This positions biopharmaceutical cell culture among the fastest-scaling segments in the broader life sciences tools and services industry.

The biopharmaceutical cell culture market covers the full range of products, technologies, and services used to grow living cells outside the body for the production of biological medicines. This includes culture media, sera, reagents, growth factors, bioreactors, and related consumables and equipment used across drug discovery, clinical development, and commercial manufacturing.

The market excludes finished biopharmaceutical drug products themselves. Instead, it captures the upstream and midstream inputs that make biological drug manufacturing possible. This distinction matters because suppliers in this market serve multiple therapeutic categories simultaneously, making revenue far less dependent on the success of any single drug or molecule.

Biopharmaceutical cell culture sits at the production foundation of the global biologics industry. Every monoclonal antibody, vaccine, biosimilar, and cell or gene therapy that reaches patients depends on a functional cell culture process. This structural dependency means that as the biologics pipeline expands, demand for cell culture inputs expands in parallel — with limited substitution risk.

The current state of the market reflects a global manufacturing build-out. As reported by Samsung Biologics, the company expanded total biopharmaceutical cell culture production capacity toward 784,000 liters with Plant 5 at Bio Campus II in Incheon, South Korea, scheduled to begin operations in April 2025, while also considering a sixth plant that would bring total capacity to 964,000 liters. This level of capital commitment signals that large CDMOs are betting heavily on sustained biologics outsourcing demand.

Single-use technology has reshaped how cell culture manufacturing is structured. Based on data from BioPlan Associates' 21st Annual Report, single-use systems adoption in biopharmaceutical cell culture manufacturing reached 87% in 2024. This shift away from traditional stainless-steel equipment reduces changeover time and lowers contamination risk, compressing the cost structure for manufacturers who previously required dedicated facilities per product.

The outsourcing model continues to gain commercial weight. Samsung Biologics recorded consolidated revenue of KRW 4.55 trillion (approximately USD 3.16 Billion) from biopharmaceutical contract development and manufacturing services in FY2024, a 23% year-over-year increase, driven by full utilization of Plants 1 through 3 and increased contribution from Plant 4. This performance confirms that large-scale cell culture CDMO capacity is operating at or near full utilization — a structural signal that new capacity additions will be absorbed quickly.

Geographic diversification of manufacturing is accelerating. Pfizer opened a SGD 1 Billion (approximately USD 743 Million) pharmaceutical manufacturing facility in Singapore in July 2024, and Novartis broke ground on a USD 256 Million biologics manufacturing expansion in Singapore in March 2024. These investments confirm that Asia-Pacific is no longer a secondary manufacturing hub — it is becoming a primary production base for global biopharmaceutical supply chains.

Market Size and Forecast

The Biopharmaceutical Cell Culture Market was valued at USD 13.28 Billion in 2025. North America accounts for 39.8% of this total, with the US alone contributing USD 7.13 Billion. This concentration in a single country reflects the depth of the US biologics manufacturing base and its pipeline of approved and late-stage biologic therapies requiring large-scale cell culture production.

The market is forecast to reach USD 62.37 Billion by 2035, expanding at a CAGR of 16.9% over the 2026 to 2035 period. China, valued at USD 6.63 Billion in 2025 and growing at 15.9%, will likely emerge as the second-largest national market by the end of the forecast period. This dual-engine growth across the US and China structurally reduces the market's dependence on any single regulatory or trade environment.

The forecast assumptions rest on three observable foundations: continued CDMO capacity expansion, accelerating biosimilar approvals, and sustained single-use technology adoption. The US FDA approved 18 new biosimilars in 2024, breaking its annual record, and brought the cumulative total to 63 approved biosimilars as reported by JD Supra. Each new biosimilar approval translates directly into new cell culture production demand — either at originator facilities or at contract manufacturers.

An upside scenario emerges if Asia-Pacific manufacturing investments come online ahead of schedule and absorb a larger share of global biologics outsourcing. Samsung Biologics entered 2025 with a record single contract order worth KRW 2 Trillion and set a consolidated revenue growth target of 20% to 25% for 2025, as confirmed by the company. If this growth rate is sustained across multiple CDMOs, the market could track above the base CAGR forecast well before 2030.

A downside scenario materializes if regulatory tightening disrupts manufacturing timelines. The FDA conducted 989 drug quality assurance inspections in fiscal year 2024, a 27% increase from 776 inspections in FY2023, according to BioPlan Associates data. The agency also issued 190 warning letters to drug and biologics manufacturers in FY2024. A sustained increase in enforcement actions could delay facility approvals, slow capacity utilization, and compress near-term revenue growth for cell culture suppliers.

Market Dynamics

Global Monoclonal Antibody and Biosimilar Manufacturing Expansion Drives Sustained Cell Culture Capacity Investment

Large-scale capacity additions by both originator manufacturers and CDMOs are creating direct and sustained demand for cell culture inputs. As reported by Business Wire, Thermo Fisher Scientific expanded 58,000 square feet of biologics manufacturing space in St. Louis, integrating four 5,000L single-use bioreactors in 2024. Expansions of this scale require proportional increases in media, sera, reagents, and process consumables — making cell culture suppliers direct beneficiaries of every new bioreactor line commissioned.

Biologics outsourcing has reached a scale that structurally supports the cell culture market regardless of any single company's pipeline performance. Samsung Biologics signed a USD 1.24 Billion contract manufacturing agreement in 2024 and secured 17 of the global top 20 pharmaceutical companies as clients as of FY2024, with a cumulative contract value of USD 16.3 Billion, as confirmed by the company. This breadth of client relationships insulates CDMO-linked cell culture demand from the risk of individual drug failures.

Biosimilar competition is adding another layer of structural demand. The FDA broke its annual record for biosimilar approvals in 2024 by authorizing 18 new biosimilars referencing eight different molecules, as reported by JD Supra. Each approval triggers a new commercial manufacturing program that requires dedicated cell culture capacity — meaning regulatory progress in biosimilars directly converts into cell culture consumable and equipment procurement decisions.

High Capital Requirements and Intensifying Regulatory Scrutiny Constrain Rapid Market Expansion

Building and validating biopharmaceutical cell culture manufacturing capacity requires capital commitments that most mid-size organizations cannot sustain independently. Thermo Fisher Scientific pursued multi-site infrastructure expansion projects in 2024, as noted by Business Wire, while Amgen announced a USD 1 Billion investment in December 2024 to establish a second drug substance manufacturing facility in Holly Springs, North Carolina, bringing its total planned investment at that site to more than USD 1.5 Billion. These figures confirm that meaningful capacity additions require resources available only to large, well-capitalized players.

Regulatory oversight of biologics manufacturing has intensified sharply. The FDA conducted 989 drug quality assurance inspections in FY2024, a 27% increase from FY2023, with more than 62% of inspections conducted at foreign sites — an all-time high for foreign inspection activity, according to BioPlan Associates data. This elevated scrutiny creates compliance cost burdens and timeline uncertainty for manufacturers operating cell culture facilities across multiple geographies.

Manufacturing facility deficiencies are now the most common factor in Complete Response Letters for biologics, based on an analysis of more than 100 BLA CRLs from 2014 to 2024, as reported by Citeline Insights. When facility issues delay a BLA approval, the associated cell culture production programs lose commercial revenue for the duration of remediation. This regulatory drag acts as a ceiling on how quickly approved capacity translates into active production revenue for cell culture suppliers.

Asia-Pacific Manufacturing Build-Out and Single-Use Technology Deployment Open New Commercial Pathways

Asia-Pacific is emerging as the most capital-active region for new biopharmaceutical cell culture capacity. Pfizer opened a SGD 1 Billion manufacturing facility in Singapore in July 2024, Novartis broke ground on a USD 256 Million biologics expansion in Singapore in March 2024, and AstraZeneca announced a USD 1.5 Billion ADC manufacturing facility in Singapore in May 2024, as reported by their respective company announcements. These investments collectively create a new geographic concentration of cell culture demand that did not exist at this scale five years ago.

India presents a distinct commercial pathway through its biosimilar manufacturing base. As reported by CII, India accounts for 28% of globally approved biosimilars, with 123 biosimilars launched and over 100 in the pipeline as of 2024, with the country's bio-economy reaching USD 130 Billion in 2024. Aurobindo Pharma separately announced plans to invest up to Rs 1,000 crore (approximately USD 120 Million) in a biologics manufacturing plant targeting biosimilar contract manufacturing. India's cost structure makes it an attractive destination for lower-margin, high-volume cell culture production.

Single-use technology deployment creates a recurring consumable revenue model that benefits cell culture suppliers with broad product portfolios. Among biopharmaceutical manufacturers, 41% identified disposable and single-use products as their largest budget item, and 31.3% said the same of single-use bioreactors, according to BioPlan Associates survey data. Suppliers who can offer integrated single-use solutions — from bioreactors to bags, connectors, and sensors — are positioned to capture a larger share of per-facility spending than those offering point solutions.

Market Trends

CDMO Consolidation, Single-Use Adoption, and Regional Manufacturing Diversification Are Reshaping the Competitive Structure of Biopharmaceutical Cell Culture

Long-term outsourcing contracts are extending well beyond typical procurement cycles. Samsung Biologics secured multiple billion-dollar manufacturing agreements extending through 2037 during 2024, as reported by the company. Contracts of this duration lock in cell culture consumable and media supply relationships for years, creating captive revenue streams for preferred suppliers and raising the switching cost for manufacturers mid-contract.

Single-use bioreactor adoption has plateaued in terms of facility penetration but is expanding in volume throughput. Based on data from BioPlan Associates, 85.2% of biopharmaceutical manufacturing facilities used single-use bioreactors as of 2024, essentially unchanged from 84.3% in 2020. However, single-use suppliers reported an average 13.5% increase in volume shipped between June 2023 and July 2024, and projected 28.5% volume growth over the following 12 months. The market has moved from adoption to intensification — meaning growth now comes from more units per facility, not more facilities adopting the technology.

Global biomanufacturing capacity expansion is concentrating in Asia while Western facilities focus on validation and commercial utilization. South Korea's biopharmaceutical exports increased 46.0% to KRW 6.274 Trillion in 2024 from KRW 4.298 Trillion in 2023, as reported by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. AGC Biologics separately commenced construction of a 215,000 square-foot mammalian cell culture facility in Yokohama, Japan, funded partly by a METI grant. Early movers who establish cell culture supply relationships with Asian CDMOs now will face fewer competitors than those who wait until these facilities reach full commercial utilization.

Product Analysis

Consumables dominate with 73.6% due to recurring single-use procurement cycles.

In 2025, Consumables held a dominant market position in the By Product segment of the Biopharmaceutical Cell Culture Market, with a 73.6% share. This dominance reflects the non-negotiable recurring nature of consumable procurement — every cell culture run requires fresh media, sera, reagents, and single-use components regardless of facility size or therapeutic area. The structural shift toward single-use bioprocessing reinforces this position, as single-use systems replace durable equipment with disposable components that must be repurchased with every production batch.

Equipment represents the capital investment layer of the cell culture market, covering bioreactors, filtration systems, incubators, and process monitoring tools. While equipment commands lower revenue share than consumables, it drives downstream consumable dependency — a facility that installs a specific bioreactor platform typically standardizes its media and single-use supply chain around that platform. Equipment purchasing decisions therefore function as long-term revenue locks for consumable suppliers who align their product portfolios with dominant hardware platforms.

Application Analysis

Biopharmaceutical Production leads with 12.3% CAGR due to expanding CDMO capacity globally.

In 2025, Biopharmaceutical Production held a dominant market position in the By Application segment of the Biopharmaceutical Cell Culture Market, with the highest CAGR of 12.3%. This application encompasses the commercial-scale manufacture of biologics including monoclonal antibodies, fusion proteins, and biosimilars using mammalian and other cell culture systems. The volume of active commercial manufacturing programs — supported by Samsung Biologics' 784,000-liter capacity build and Lonza's acquisition of the Genentech Vacaville facility in October 2024 — directly expands the addressable base for media, consumables, and bioprocess equipment suppliers.

Monoclonal Antibodies Production represents the single largest therapeutic category driving cell culture manufacturing demand. The FDA's approval of 18 new biosimilars in 2024, referencing eight different molecules as reported by JD Supra, has expanded the number of active mAb manufacturing programs requiring dedicated cell culture capacity. Each new mAb program — whether originator or biosimilar — requires validated cell lines, qualified media formulations, and process-specific consumable supply chains, creating layered and durable demand across the value chain.

Vaccines Production represents a strategically distinct application where cell culture has displaced egg-based and other traditional manufacturing methods for an expanding range of vaccine types. AGC Biologics commenced construction of a 215,000 square-foot mammalian cell culture facility in Yokohama, Japan, partly designed to support vaccine production, as reported by BioProcess International. Government-backed manufacturing investments in vaccine cell culture capacity — particularly across Asia — are creating a publicly funded demand base that supplements commercial biologics outsourcing.

Cell and Gene Therapy is the application segment with the most differentiated cell culture requirements. Unlike mAb or vaccine production, cell and gene therapy manufacturing often requires autologous or allogeneic cell expansion under tightly controlled conditions with patient-specific or small-batch parameters. Lonza's CORE EBITDA of CHF 1.9 Billion at a margin of 29.0% in FY2024, driven partly by its Cell and Gene Technologies business as reported by Lonza, confirms that specialized cell culture services for advanced therapies command premium pricing relative to conventional biologics manufacturing.

Drug Screening and Development applies cell culture at the earliest stages of the pharmaceutical value chain, where candidate molecules are tested against living cell systems before entering clinical trials. This application generates consistent demand for research-grade media, primary cells, immortalized cell lines, and high-throughput screening consumables. Because drug screening activity is tied to R&D investment rather than commercial manufacturing volume, it provides a counter-cyclical revenue buffer for cell culture suppliers when commercial production programs slow.

Tissue Engineering and Regenerative Medicine represents an emerging application where three-dimensional cell culture systems — including scaffold-based, bioprinting, and microfluidic platforms — are used to grow functional tissue constructs for therapeutic and research purposes. The scaffold-based segment alone held 46.43% of the 3D cell culture technology revenue share in 2025, reflecting the relative maturity of scaffold-based approaches compared to newer modalities. As this application scales toward clinical and commercial use, it will require purpose-built media formulations and specialized culture vessels that differ materially from standard 2D cell culture inputs.

Diagnostics uses cell culture systems to produce biological reagents, validate assay performance, and develop cell-based diagnostic platforms. While diagnostics represents a smaller revenue contributor relative to therapeutic manufacturing applications, it provides stable baseline demand for cell lines, culture media, and quality-control consumables. Diagnostic applications also benefit from less stringent regulatory requirements than therapeutic manufacturing, allowing faster product iteration and lower compliance cost for cell culture suppliers serving this end-use.

Type Analysis

Monoclonal Antibodies dominate with largest share due to commercial-scale mAb pipeline depth.

In 2025, Monoclonal Antibodies (mAbs) held a dominant market position in the By Type segment of the Biopharmaceutical Cell Culture Market, with the largest share. The commercial mAb pipeline is the deepest in biologics history, supported by the FDA's cumulative approval of 63 biosimilars as of end-2024 as reported by JD Supra, the majority of which reference mAb molecules. Every approved mAb — originator or biosimilar — requires ongoing cell culture-based commercial production, making this segment the most structurally secured source of recurring demand in the market.

Vaccines represent the second major type category within biopharmaceutical cell culture, encompassing both viral vector-based and protein subunit vaccine platforms that depend on mammalian or insect cell culture systems. Government-mandated stockpiling programs and pandemic preparedness investments have created a publicly funded floor of vaccine cell culture demand that exists independently of commercial market cycles. This government-backed demand base reduces revenue volatility for cell culture suppliers operating in the vaccine production segment.

Other Therapeutic Proteins include fusion proteins, cytokines, enzymes, clotting factors, and hormones produced using recombinant cell culture systems. This category benefits from the expansion of biologic drug approvals beyond the mAb class, as developers apply cell culture manufacturing expertise to increasingly complex protein structures. The diversity of molecules within this category means that cell culture media and process requirements vary significantly across programs, creating demand for customized formulations and specialized process development services.

End-User Analysis

Pharmaceutical and Biotechnology Companies dominate due to in-house commercial manufacturing scale.

In 2025, Pharmaceutical and Biotechnology Companies held a dominant market position in the By End-User segment of the Biopharmaceutical Cell Culture Market, with the largest share. These organizations operate the largest cell culture production facilities globally, procure the highest volumes of media, consumables, and equipment, and set industry standards for process validation and quality systems. Amgen's announced USD 1 Billion investment in a second drug substance manufacturing facility in North Carolina, as reported by the North Carolina Department of Commerce, illustrates the scale at which top-tier biopharma companies continue to invest in owned cell culture capacity.

Hospitals and Diagnostic Laboratories use cell culture primarily for diagnostic assay development, pathogen identification, and small-scale production of biological reference materials. This end-user segment generates consistent but volume-limited demand for research-grade cell culture products. As point-of-care diagnostics and cell-based assay platforms expand, hospitals and diagnostic laboratories represent a growing channel for cell culture consumable suppliers seeking to diversify beyond pharmaceutical manufacturing customers.

Research and Academic Institutes form the foundational demand layer for basic cell culture products including primary cells, immortalized cell lines, standard media formulations, and low-volume research reagents. Academic institutions train the next generation of cell culture scientists, driving long-term familiarity with specific supplier platforms and product lines. Suppliers who establish strong relationships with academic institutions benefit from brand continuity as researchers move into industrial and clinical roles and carry procurement preferences with them.

CROs and CMOs represent the fastest-evolving end-user category, driven by the global outsourcing of biopharmaceutical development and manufacturing. Lonza achieved contract signings worth approximately CHF 10 Billion in 2024, reflecting strong order momentum across its CDMO business including mammalian cell culture and biologics manufacturing services, as reported by Lonza. The growth of this end-user segment is self-reinforcing: as more drug developers outsource manufacturing, CDMOs expand capacity, which in turn increases their aggregate procurement of cell culture media, consumables, and process equipment.

Technology Analysis

2D Cell Culture dominates with largest share due to established process validation and regulatory precedent.

In 2025, 2D Cell Culture held a dominant market position in the By Technology segment of the Biopharmaceutical Cell Culture Market, with the largest share. Two-dimensional cell culture systems — where cells grow as monolayers on flat surfaces — underpin the majority of existing commercial biopharmaceutical manufacturing processes. Decades of process validation data, established regulatory filing precedents, and deep supplier ecosystems create switching costs that protect 2D systems from rapid displacement, even as alternative technologies mature.

3D Cell Culture is the segment attracting the highest level of technology development investment, particularly for applications in cell therapy, tissue engineering, and advanced disease modeling. Scaffold-based 3D systems held 46.43% of the 3D cell culture technology revenue share in 2025, reflecting their relative commercial maturity. However, scaffold-free, microfluidic, and bioprinting approaches are each building application-specific commercial cases that will expand the overall 3D cell culture addressable market through the forecast period.

Perfusion Cell Culture enables continuous feeding and waste removal during production, allowing higher cell densities and extended culture durations compared to fed-batch processes. This technology is increasingly relevant for high-value biologic molecules where yield per liter is a critical economic variable. As manufacturers seek to extract more output from existing bioreactor footprints — rather than building new stainless-steel capacity — perfusion adoption is likely to accelerate, driving demand for specialized media formulations and filtration consumables designed for continuous operation.

High-Throughput Cell Culture applies automation and miniaturization to run large numbers of parallel cell culture experiments simultaneously, primarily in drug discovery and process development applications. BioPlan Associates surveyed 220 qualified individuals at biopharmaceutical manufacturers and CMOs across 23 countries for its 21st Annual Report, confirming that process development efficiency remains a top organizational priority. High-throughput platforms that reduce media consumption per experiment and accelerate process optimization timelines offer measurable cost advantages that translate directly into procurement decisions.

Raw Material Analysis

Media dominates consumables segment due to continuous consumption across all cell culture processes.

In 2025, Media held a dominant market position within the consumables segment of the Biopharmaceutical Cell Culture Market. Cell culture media — the nutrient-rich liquid that sustains cell growth and productivity — is consumed in every cell culture run at every scale, from research flasks to commercial bioreactors. China's cell culture media imports reached USD 385.34 Million and 4.71 kilotons in 2024, marking 18.54% growth in value with the United States supplying 61.3% of total imports, as reported by UN Comtrade data. This import dependency signals both the scale of global media demand and the concentration of supply among a small number of established manufacturers.

Sera, primarily fetal bovine serum (FBS), provides essential growth factors and proteins that synthetic media formulations cannot yet fully replicate for all cell types and applications. Supply constraints and ethical concerns around animal-derived sera are driving investment in serum-free and chemically defined media alternatives. Suppliers who successfully develop validated serum-free formulations for high-value cell culture applications — particularly in cell and gene therapy — will capture premium pricing and reduce their exposure to the inherent supply volatility of animal-derived raw materials.

Reagents encompass a broad category of biological and chemical inputs used for cell culture preparation, maintenance, and analysis, including antibiotics, buffers, dissociation enzymes, and detection reagents. This category benefits from the expansion of cell culture applications beyond standard therapeutic protein production into diagnostics, tissue engineering, and gene therapy, each of which requires application-specific reagent portfolios. Suppliers with broad reagent catalogs and application-specific formulation expertise hold a structural advantage over those competing on price alone in commodity reagent categories.

Vessels include the physical containers used for cell culture at research and production scale — from multi-well plates and flasks to single-use bags and bioreactor vessels. The industry-wide adoption of single-use systems has fundamentally changed the vessel market from a capital-intensive, reusable equipment model to a recurring consumable procurement model. Among biopharmaceutical manufacturers, 41% identified disposable and single-use products as their largest budget item in 2024, according to BioPlan Associates survey data, confirming that vessel procurement now represents the largest single expenditure category in cell culture operations.

Growth Factors and Cytokines are high-value biological molecules added to cell culture systems to direct cell differentiation, proliferation, and function. These inputs are particularly critical in cell and gene therapy manufacturing, where precise control of cell phenotype is a product quality attribute rather than simply a process parameter. The premium pricing of growth factors and cytokines relative to bulk media components means that cell culture manufacturers who supply this category generate disproportionately high revenue per unit volume compared to commodity consumable suppliers.

Buffers and Chemicals provide the pH control, osmolality management, and chemical environment required for consistent cell culture performance across production batches. While individually lower in value than media or growth factors, buffers and chemicals are consumed in large volumes across every stage of bioprocessing — from cell culture through purification and formulation. Merck KGaA's Process Solutions business unit, which includes cell culture media and bioprocessing chemicals, generated sales of EUR 3,523 Million in FY2024, accounting for 40% of the Life Science segment sales of EUR 8,916 Million, as reported by Merck KGaA. This revenue scale confirms that broad-portfolio chemistry and consumable suppliers capture substantial value from the buffers and chemicals category.

3D Cell Culture Technology Analysis

Scaffold-based systems dominate with 46.43% due to established regulatory and commercial precedent.

In 2025, Scaffold-based systems held a dominant market position in the By 3D Cell Culture Technology segment of the Biopharmaceutical Cell Culture Market, with a 46.43% revenue share. Scaffold-based approaches use physical matrices — synthetic polymers, hydrogels, or biological materials — to provide structural support that mimics the extracellular environment cells experience in living tissue. This physical mimicry improves cell behavior and experimental relevance compared to 2D monolayer culture, making scaffold-based 3D systems the default choice for tissue engineering, organoid development, and advanced disease modeling applications.

Scaffold-free 3D cell culture systems allow cells to self-aggregate into spheroids or organoids without external support matrices, producing tissue constructs with more physiologically authentic intercellular interactions. This approach is gaining traction in drug toxicity screening and tumor biology research, where the absence of scaffold material eliminates a confounding variable in experimental results. As pharmaceutical companies adopt scaffold-free spheroid models earlier in drug discovery workflows, demand for the specialized ultra-low attachment vessels and aggregation-optimized media required for these systems is expanding.

Microfluidics-based cell culture platforms miniaturize the cell culture environment into chip-scale systems that recreate organ-level physiological conditions, including fluid flow, mechanical stress, and multi-tissue interfaces. These organ-on-a-chip systems are attracting investment from pharmaceutical companies seeking to reduce animal testing and improve the predictive accuracy of preclinical drug screening. While still in early commercial adoption, microfluidic cell culture platforms require highly specialized media formulations, surface coatings, and detection reagents that command premium pricing relative to conventional cell culture inputs.

Bioprinting uses additive manufacturing techniques to deposit cells and biomaterials in precise three-dimensional patterns, enabling the construction of complex tissue architectures that cannot be achieved through conventional cell culture methods. This technology is primarily at the research and early clinical development stage, with commercial therapeutic applications still several years from regulatory approval in most markets. However, bioprinting is already creating demand for bioink formulations — cell-laden hydrogels with specific rheological and biological properties — representing a new product category for cell culture raw material suppliers.

Single-Use Systems Analysis

Single-Use Bioreactors dominate due to widespread commercial-scale adoption across CDMO networks.

In 2025, Single-Use Bioreactors held a dominant market position in the By Single-Use Systems segment of the Biopharmaceutical Cell Culture Market. Based on data from BioPlan Associates, 85.2% of biopharmaceutical manufacturing facilities used single-use bioreactors as of 2024. The average size of the largest bioreactors in use at global facilities declined from 4,718 liters in 2017 to 3,664 liters in 2024, confirming that the industry has pivoted toward flexible, modular single-use systems rather than large fixed stainless-steel tanks. Thermo Fisher Scientific's integration of four 5,000L DynaDrive single-use bioreactors into its expanded St. Louis facility in 2024, as reported by Business Wire, reflects the commercial standard now being set for new facility builds.

Single-Use Filtration Systems handle clarification, concentration, and purification steps downstream of the cell culture bioreactor, and their adoption tracks directly with single-use bioreactor penetration. As more manufacturers convert to fully single-use processing trains — from cell culture through final filtration — the demand for single-use filtration assemblies grows in proportion to production volume rather than facility count. Sartorius reported order intake of EUR 3,377.5 Million in FY2024, representing 10.8% growth in constant currency, with the Bioprocess Solutions division consumables business showing increasingly positive trends, as confirmed by Sartorius. This recovery in order flow confirms that the post-destocking normalization in single-use filtration consumables is advancing.

Single-Use Storage Systems include bioprocess bags, carboys, and containers used to store media, intermediates, and bulk drug substance in sterile single-use formats. The shift to single-use storage eliminates cleaning validation requirements and reduces cross-contamination risk between batches — a compliance advantage that carries measurable value for facilities operating multiple concurrent product campaigns. As CDMO facilities run more simultaneous client programs within shared physical footprints, single-use storage adoption becomes a facility management imperative rather than simply a technology preference.

Tubing and Connectors form the fluid transfer infrastructure of single-use bioprocessing systems, connecting bioreactors, filtration assemblies, and storage containers within a closed, sterile fluid path. While individually low in unit value, tubing and connectors are consumed in high volumes across every production run and represent a significant aggregate procurement category for large-scale manufacturing facilities. Among biopharmaceutical manufacturers, 41% identified disposable and single-use products including bags and connectors as their largest budget item in 2024, per BioPlan Associates survey data, underscoring the commercial weight of this product category.

Single-Use Sensors and Probes monitor critical process parameters — pH, dissolved oxygen, temperature, and cell density — within single-use bioreactor systems without requiring sterilization or recalibration between runs. The integration of single-use sensing into process analytical technology frameworks is a prerequisite for real-time process control and continuous manufacturing approaches. As regulatory agencies place greater emphasis on process understanding and in-line monitoring — reflected in the FDA's 989 inspections in FY2024 including scrutiny of process control and data integrity — single-use sensor adoption becomes a compliance-driven procurement decision as much as a technical one.

Cell Line Type Analysis

Primary Cells lead research applications due to physiological relevance in early-stage drug discovery.

In 2025, Primary Cells held a significant position in the By Cell Line Type segment of the Biopharmaceutical Cell Culture Market. Primary cells — isolated directly from living tissue and used without genetic modification — provide the closest available approximation of in vivo cell behavior for research and drug screening applications. Their biological authenticity makes them the preferred cell system for toxicology studies and target validation work, where experimental relevance directly affects the predictive value of preclinical data for clinical outcomes.

Immortalized Cell Lines are genetically stable cell populations that proliferate indefinitely under standard culture conditions, providing reproducibility and scalability that primary cells cannot match. Chinese Hamster Ovary (CHO) cells — the dominant immortalized cell line in commercial biologics manufacturing — underpin the majority of approved monoclonal antibody and therapeutic protein production processes. The deep body of regulatory filing precedent built around CHO cell culture processes creates a structural preference for this system in commercial manufacturing that will persist through the forecast period.

Stem Cells represent the highest-complexity and highest-value cell type in the biopharmaceutical cell culture market, serving as the starting material for cell therapy manufacturing and as research tools for disease modeling and drug discovery. The specialized media, growth factor cocktails, and surface coating requirements for stem cell culture generate premium revenue per unit volume for suppliers who develop validated stem cell culture systems. Lonza's Cell and Gene Technologies business contributing to its CHF 1.9 Billion CORE EBITDA at 29.0% margin in FY2024, as reported by Lonza, reflects the commercial value generated at the stem cell and advanced therapy end of the cell culture market.

Genetically Engineered Cell Lines include cells modified to express specific receptors, reporters, or therapeutic proteins for research, screening, and production applications. In manufacturing, genetically engineered producer cell lines are the foundation of every recombinant biologic production process — the quality and productivity of the cell line directly determines the economics of the manufacturing campaign. WuXi Biologics' total integrated project count reached 817 projects in FY2024, including 151 new integrated projects added during the year, as reported by Market Screener, reflecting the volume of new cell line development and engineering work required to sustain a pipeline of this scale.

Key Market Segments

By Product

• Consumables
• Equipment

By Application

• Biopharmaceutical Production
• Monoclonal Antibodies Production
• Vaccines Production
• Cell and Gene Therapy
• Drug Screening and Development
• Tissue Engineering and Regenerative Medicine
• Diagnostics

By Type

• Monoclonal Antibodies (mAbs)
• Vaccines
• Other Therapeutic Proteins

By End-User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Research and Academic Institutes
• CROs and CMOs

By Technology

• 2D Cell Culture
• 3D Cell Culture
• Perfusion Cell Culture
• High-Throughput Cell Culture

By Raw Material

• Media
• Sera
• Reagents
• Vessels
• Growth Factors and Cytokines
• Buffers and Chemicals

By 3D Cell Culture Technology

• Scaffold-based
• Scaffold-free
• Microfluidics
• Bioprinting

By Single-Use Systems

• Single-Use Bioreactors
• Single-Use Filtration Systems
• Single-Use Storage Systems
• Tubing and Connectors
• Single-Use Sensors and Probes

By Cell Line Type

• Primary Cells
• Immortalized Cell Lines
• Stem Cells
• Genetically Engineered Cell Lines

Regional Analysis

North America Dominates the Biopharmaceutical Cell Culture Market with a Market Share of 39.8%, Valued at USD 7.13 Billion

North America holds the largest regional share of the Biopharmaceutical Cell Culture Market at 39.8%, with the US contributing USD 7.13 Billion and accounting for 87.8% of the regional total in 2025. The US market grows at a CAGR of 15.3%. This dominance reflects the concentration of large originator biopharmaceutical manufacturers, leading CDMO networks, and the world's most active biologics regulatory environment — where the FDA approved 16 BLAs and a record 18 biosimilars in 2024 alone, as reported by JD Supra. Every new approval generates a corresponding commercial manufacturing program that procures cell culture inputs from US-based or US-serving suppliers.

Europe Biopharmaceutical Cell Culture Market Trends

Europe maintains a strong position in biopharmaceutical cell culture through its established CDMO infrastructure and life sciences manufacturing base in Switzerland, Ireland, and Germany. Ireland's exports of medical and pharmaceutical products rose 29% to EUR 99.9 Billion in 2024, accounting for 45% of all goods exports from the country, as reported by the Central Statistics Office of Ireland. Switzerland's biotech industry generated total revenues of CHF 7.2 Billion in 2024, with R&D investments increasing to CHF 2.6 Billion from CHF 2.4 Billion in 2023, as reported by Swiss Biotech Association. These figures confirm Europe's role as both a manufacturing base and an innovation hub for biopharmaceutical cell culture.

Asia Pacific Biopharmaceutical Cell Culture Market Trends

Asia Pacific is the fastest-scaling region for new biopharmaceutical cell culture capacity, driven by coordinated public and private investment across South Korea, Singapore, China, Japan, and India. South Korea's biopharmaceutical exports increased 46.0% to KRW 6.274 Trillion in 2024, as reported by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. China's cell culture media imports reached USD 385.34 Million in 2024, growing 18.54% in value, with the US supplying 61.3% of total imports, per UN Comtrade data. Singapore's biomedical sector employed more than 9,000 workers across over 60 manufacturing facilities as of 2024, reflecting a 70% increase in sector employment over the past decade, as reported by Singapore's EDB. The region's combination of cost competitiveness, government incentives, and growing regulatory sophistication makes it the most dynamic geography for cell culture market expansion.

Latin America Biopharmaceutical Cell Culture Market Trends

Latin America remains an early-stage market for biopharmaceutical cell culture, with Brazil and Mexico representing the primary commercial opportunities. The region's biologics manufacturing base is nascent compared to North America and Asia Pacific, but biosimilar adoption is accelerating as healthcare systems seek lower-cost alternatives to originator biologics. Cell culture suppliers entering Latin America face infrastructure limitations and fragmented regulatory frameworks across national markets, but early positioning in Brazil — the region's largest pharmaceutical market — offers first-mover advantages as domestic biologics manufacturing investment increases.

Middle East and Africa Biopharmaceutical Cell Culture Market Trends

The Middle East and Africa region represents a small but strategically relevant segment of the global biopharmaceutical cell culture market, primarily driven by GCC countries investing in domestic pharmaceutical manufacturing capacity. Government-backed initiatives across Saudi Arabia and the UAE to reduce pharmaceutical import dependency are creating early-stage demand for cell culture equipment and consumables. South Africa maintains the most developed biopharmaceutical infrastructure on the African continent, though the region as a whole remains dependent on imports for the majority of cell culture inputs, presenting a long-term distribution and localization opportunity for global suppliers.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of MEA

Competitive Landscape

The Biopharmaceutical Cell Culture Market is moderately consolidated at the top, with a small number of large diversified life sciences companies controlling the majority of media, consumable, and equipment supply, while a longer tail of specialized suppliers competes in specific product or application niches. This structure reflects the capital intensity of developing validated cell culture platforms and the regulatory complexity of qualifying new suppliers within biopharmaceutical manufacturing environments.

Market leaders maintain their position through portfolio breadth rather than single-product dominance. Merck KGaA's Process Solutions business unit generated sales of EUR 3,523 Million in FY2024, accounting for 40% of the company's Life Science segment sales of EUR 8,916 Million, as reported by Merck KGaA. Suppliers who can offer integrated solutions — from cell culture media through purification consumables and process equipment — reduce the procurement complexity for biopharmaceutical manufacturers and create multi-product account relationships that are difficult for single-category competitors to displace.

The CDMO segment of the competitive landscape is consolidating rapidly through capacity expansion and strategic acquisitions. Lonza closed the acquisition of the Genentech large-scale mammalian cell culture manufacturing facility in Vacaville, California from Roche on October 1, 2024, and immediately signed two new customer contracts for biologics production at the site, as reported by Lonza. Acquisitions of operational manufacturing sites — rather than greenfield builds — accelerate market position gains and reduce the timeline from investment to revenue generation.

Share dynamics are shifting toward suppliers with strong single-use portfolios and Asia-Pacific manufacturing presence. Sartorius reported order intake of EUR 3,377.5 Million in FY2024, representing 10.8% growth in constant currency, as reported by Sartorius, suggesting a recovery in consumable procurement after the post-pandemic destocking cycle. Companies that expanded capacity during the destocking period — accepting near-term margin pressure — are positioned to capture disproportionate share as procurement volumes normalize and new Asian CDMO facilities reach operational maturity.

Partnership activity is emerging as a competitive differentiator alongside M&A. Sartorius Stedim Biotech partnered with Sensible Biotechnologies in July 2025 to scale a cell-based mRNA manufacturing platform, as reported by Sartorius. These technology partnerships allow established cell culture suppliers to extend their platforms into emerging modalities — such as mRNA and cell therapy — without bearing the full R&D cost of internal platform development, while simultaneously securing preferred supplier positions in new manufacturing ecosystems before competition intensifies.

Company Profiles

Thermo Fisher Scientific Inc. operates as the market's most vertically integrated cell culture supplier, combining media formulation, single-use bioprocessing equipment, and CDMO services within a single organizational structure. The company expanded 58,000 square feet of biologics manufacturing space in St. Louis in 2024, integrating four 5,000L DynaDrive single-use bioreactors, as reported by Business Wire. This dual role as both supplier and manufacturer gives Thermo Fisher direct insight into customer process requirements — a competitive intelligence advantage that informs product development priorities and service offering design.

Sartorius AG anchors its competitive position in the bioprocess equipment and single-use consumables segments, where its filtration, fluid management, and bioreactor platforms are embedded in a large proportion of global biopharmaceutical manufacturing facilities. The Bioprocess Solutions division generated revenue of approximately EUR 2.69 Billion in FY2024, representing approximately 80% of total company sales of EUR 3.38 Billion, as reported by Sartorius. The company's partnership with Sensible Biotechnologies to scale a cell-based mRNA manufacturing platform in July 2025 signals a strategic intent to extend platform relevance into next-generation biomanufacturing modalities before competitors establish equivalent capabilities.

Merck KGaA competes through the breadth of its Life Science portfolio, which spans cell culture media, process chemicals, filtration products, and CDMO services under a single commercial relationship for biopharmaceutical customers. The company's Life Science Services CDMO business recorded sales of EUR 722 Million in FY2024, a decline from EUR 792 Million in FY2023, representing an organic sales decline of 9.4%, as reported by Merck KGaA — driven by a customer-specific supply chain adjustment rather than broad market weakness. The ability to absorb CDMO softness while maintaining Process Solutions revenue at EUR 3,523 Million demonstrates the risk-buffering value of portfolio diversification across cell culture product categories.

Lonza Group Ltd. has established the most commercially aggressive position among large-scale biologics CDMOs, combining mammalian cell culture manufacturing expertise with a rapidly expanding facility network. The company delivered CDMO business sales of CHF 6.6 Billion in FY2024 and invested CHF 1.4 Billion in capital expenditures representing 22% of sales, while achieving contract signings worth approximately CHF 10 Billion during the year, as reported by Lonza. Reinvesting more than one-fifth of annual revenue into capacity expansion while simultaneously filling that capacity with a record contract backlog represents a compounding competitive advantage that smaller CDMO competitors cannot replicate without access to equivalent capital.

Key Players

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Sartorius AG
• Merck KGaA
• Corning Incorporated
• FUJIFILM Holdings Corporation
• BD
• GE Healthcare (Cytiva)
• Lonza Group Ltd.
• Caisson Labs
• Solida Biotech GmbH
• Bio-Techne Corp
• PromoCell GmbH
• Avantor Inc

Supply Chain and Value Chain Analysis

The biopharmaceutical cell culture value chain begins with raw material suppliers — producers of amino acids, vitamins, lipids, salts, and biological components such as growth factors, cytokines, and animal-derived sera — who formulate inputs that flow into media and reagent manufacturers. This upstream layer is characterized by a small number of qualified raw material suppliers per ingredient category, creating concentration risk that propagates through the entire chain whenever a single-source ingredient faces supply disruption.

The middle layer of the chain — cell culture media and consumable manufacturers — captures the largest share of value-added margin by converting raw materials into validated, regulatory-grade products that biopharmaceutical manufacturers can integrate directly into GMP production processes. Merck KGaA's Process Solutions unit, generating EUR 3,523 Million in FY2024 sales as reported by Merck KGaA, and Sartorius' Bioprocess Solutions division, generating approximately EUR 2.69 Billion in FY2024 revenue as reported by Sartorius, illustrate the commercial scale that validated media and consumable suppliers achieve within this value chain position.

Equipment manufacturers — bioreactor, filtration, and fluid management system producers — sit alongside media suppliers in the middle chain but operate on a different commercial model: capital sale followed by long-term consumable attachment. The industry's shift toward single-use systems has blurred the boundary between equipment and consumable revenue, as single-use bioreactor assemblies are replaced with each production run rather than cleaned and reused. BioPlan Associates data confirms that 85.2% of biopharmaceutical manufacturing facilities used single-use bioreactors in 2024, anchoring recurring consumable revenue to equipment installation base.

The downstream layer — biopharmaceutical manufacturers and CDMOs — integrates cell culture inputs into licensed GMP manufacturing processes that produce drug substance for clinical and commercial supply. Samsung Biologics, with a cumulative contract value of USD 16.3 Billion and 340 regulatory manufacturing approvals by December 2024 as reported by the company, represents the commercial endpoint of the value chain — the point where cell culture inputs convert into approved biologic drug substance. The concentration of large-volume manufacturing at a small number of CDMO facilities creates significant buyer power that affects pricing dynamics for upstream media and consumable suppliers.

The most significant bottleneck in the current chain is raw material qualification and supply continuity for critical cell culture media components. China's import dependency — with cell culture media imports of USD 385.34 Million in 2024, with the US supplying 61.3% of total value, per UN Comtrade data — illustrates how geographically concentrated raw material supply creates systemic vulnerability for a global manufacturing base. Biopharmaceutical manufacturers and their CDMO partners who invest in dual-source qualification for critical media raw materials are reducing supply chain risk that their competitors continue to carry.

 

Regulatory Landscape

The regulatory environment governing biopharmaceutical cell culture manufacturing is among the most demanding of any industrial sector, with requirements spanning facility design, process validation, contamination control, data integrity, and supply chain qualification. The FDA's Current Good Manufacturing Practice regulations for sterile drug products set the baseline compliance standard for cell culture-based biologic manufacturing in the US market, with equivalent frameworks enforced by the EMA in Europe and the PMDA in Japan.

FDA inspection activity intensified sharply in FY2024. The agency conducted 989 drug quality assurance inspections, a 27% increase from 776 inspections in FY2023, with more than 62% of inspections conducted at foreign sites — an all-time high for foreign inspection activity, as reported by BioPlan Associates. This geographic shift in inspection focus directly affects Asian CDMO facilities, where the pace of capacity expansion has outpaced the maturation of quality systems in some organizations.

Warning letter issuance reached its highest level in five years. The FDA issued 190 warning letters to drug and biologics manufacturers in FY2024, of which 113 were based on an FDA inspection, as reported by BioPlan Associates. Additionally, 93% of all sites in the CDER Site Catalog received No Action Indicated or Voluntary Action Indicated as their most recent inspection classification — meaning the warning letter burden is concentrated among a minority of facilities, but the consequences for those facilities include manufacturing suspension and supply chain disruption that affects the entire cell culture input ecosystem.

Manufacturing facility deficiencies have become the primary regulatory barrier to biologics approval. Based on analysis of more than 100 BLA Complete Response Letters from 2014 to 2024, as reported by Citeline Insights, facility inspection issues were identified as the fastest-growing factor in the rise of CRLs for Biologics License Applications. Deficiencies cited in 2024 inspections included microbiological contamination in aseptic processing, data integrity failures, and process control and variability concerns at the bioreactor level, as reported by Redica Systems. Each CRL delays commercial manufacturing launch, directly postponing cell culture consumable procurement ramp-up for the affected program.

Biosimilar regulation is creating a parallel approval pathway that expands the addressable market for cell culture manufacturing while adding complexity. The FDA authorized 18 new biosimilars in 2024, breaking its annual approval record and bringing the cumulative total to 63 approved biosimilars referencing eight different molecules, as reported by JD Supra. Each biosimilar approval requires a separate manufacturing facility approval with its own inspection and qualification requirements — meaning that the record biosimilar approval pace in 2024 translated directly into a higher regulatory compliance workload for cell culture manufacturers serving the biosimilar sector.

Porter's Five Forces Analysis

Threat of New Entrants — Low

Entering the biopharmaceutical cell culture market at commercial scale requires substantial capital, validated manufacturing infrastructure, and regulatory qualification that takes years to build. Lonza invested CHF 1.4 Billion in capital expenditures in FY2024 alone, representing 22% of sales, as reported by Lonza. New entrants cannot match this investment pace without access to equivalent capital, and without regulatory track records — such as Samsung Biologics' 340 manufacturing approvals by December 2024 — they cannot win contracts from large biopharmaceutical customers who require validated supplier qualification as a procurement prerequisite.

Bargaining Power of Buyers — Medium

Large biopharmaceutical manufacturers and CDMOs exercise meaningful buyer power through contract scale and multi-year procurement commitments. Samsung Biologics secured a record single contract order worth KRW 2 Trillion in January 2025 and maintained relationships with 17 of the global top 20 pharmaceutical companies, as reported by the company. However, the technical complexity of switching validated cell culture media and consumable suppliers mid-program — which requires regulatory requalification — limits the practical exercise of buyer power once a supplier relationship is embedded in an approved manufacturing process.

Bargaining Power of Suppliers — Medium

Raw material suppliers for critical cell culture media components hold concentrated market positions that give them above-average pricing influence. China's cell culture media imports showed the US supplying 61.3% of total import value of USD 385.34 Million in 2024, per UN Comtrade data, reflecting geographic concentration in upstream supply. However, large media manufacturers such as Merck KGaA — whose Process Solutions unit generated EUR 3,523 Million in FY2024 sales — have sufficient purchasing scale to partially offset supplier concentration through volume leverage and dual-source qualification programs.

Threat of Substitutes — Low

No commercially viable substitute exists for cell culture as the production method for mammalian-derived biologics including monoclonal antibodies, therapeutic proteins, and cell therapies. Alternative production systems — such as microbial fermentation, plant-based expression, or cell-free synthesis — serve different molecular classes and cannot replicate the post-translational modifications required for most approved biologic drugs. The FDA's approval of 16 BLAs in 2024, representing approximately 32% of all new drug approvals, as reported by JD Supra, confirms that cell culture-produced biologics remain the dominant modality in the new drug approval pipeline with no substitution pathway in sight.

Competitive Rivalry — High

Competitive intensity among established cell culture suppliers is high and increasing as post-pandemic destocking normalizes and new capacity comes online simultaneously across multiple players. Sartorius reported order intake growth of 10.8% in constant currency in FY2024 as reported by Sartorius, while Merck KGaA's Life Science Services CDMO business recorded an organic sales decline of 9.4% in the same period as reported by Merck KGaA — illustrating that market share is actively shifting between competitors. Price competition is intensifying in commodity consumable categories, with 32.3% of biomanufacturing professionals identifying low-cost single-use systems as the most important new product development priority in 2024, per BioPlan Associates survey data.

Investment and White Space Analysis

Current investment flows in the biopharmaceutical cell culture market are concentrated in large-scale CDMO capacity expansion and single-use manufacturing infrastructure in Asia Pacific. Pfizer opened a SGD 1 Billion manufacturing facility in Singapore in July 2024, AstraZeneca announced a USD 1.5 Billion ADC manufacturing facility in Singapore in May 2024, and Novartis broke ground on a USD 256 Million biologics manufacturing expansion in Singapore in March 2024, as reported by their respective company announcements. These commitments collectively signal that Singapore — and Asia Pacific more broadly — is the primary geographic destination for new biopharmaceutical cell culture capital in the current cycle.

The single-use systems segment presents a white space in low-cost product development that is not yet adequately served by existing suppliers. Based on BioPlan Associates survey data, 32.3% of biomanufacturing professionals identified low-cost single-use systems as the most critical new product development area for suppliers in 2024. Current single-use product pricing reflects the market power of a small number of qualified suppliers — a pricing structure that creates a commercially viable entry point for new suppliers who can achieve equivalent performance at lower cost, particularly for standard-format bags, connectors, and tubing where differentiation is limited.

India represents an underserved investment destination relative to its biosimilar manufacturing scale. India accounts for 28% of globally approved biosimilars with 123 launched and over 100 in the pipeline as of 2024, and its bio-economy reached USD 130 Billion in 2024, as reported by CII. Aurobindo Pharma's announced investment of up to Rs 1,000 crore (approximately USD 120 Million) in a biologics manufacturing plant targeting biosimilar contract manufacturing confirms that domestic capacity investment is accelerating. Cell culture media and consumable suppliers who establish local distribution and technical support infrastructure in India ahead of this capacity build will capture preferred supplier positioning before competition intensifies.

The cell and gene therapy manufacturing segment represents the highest-margin white space within the broader cell culture market. Lonza's Cell and Gene Technologies business contributed to a company-wide CORE EBITDA margin of 29.0% in FY2024, as reported by Lonza — among the highest margin profiles in the CDMO sector. The specialized media, growth factor, and process consumable requirements for autologous and allogeneic cell therapy manufacturing differ substantially from standard mAb production inputs, meaning that suppliers who develop validated cell therapy-specific product portfolios compete in a less commoditized and more defensible product category.

Early movers in the mRNA cell-based manufacturing space are establishing partnerships before the competitive field consolidates. Sartorius Stedim Biotech partnered with Sensible Biotechnologies in July 2025 to scale a cell-based mRNA manufacturing platform, as reported by Sartorius. This partnership structure — where an established cell culture supplier co-develops a manufacturing platform with an emerging biotech — gives the supplier preferred access to a new production modality before independent competitors can qualify equivalent solutions. Late entrants to mRNA cell culture manufacturing will face incumbents with validated processes, regulatory filing precedents, and established customer relationships that create switching cost barriers comparable to those protecting established mAb cell culture supply relationships today.

Recent Developments

• May 2026 — Odyssey Therapeutics raised USD 279 Million through an upsized US IPO to advance autoimmune and inflammatory disease therapies, signaling continued investor appetite for biologic drug developers that will require cell culture manufacturing capacity as programs advance toward clinical and commercial stages.
• May 2026 — Zydus Lifesciences announced a USD 166.4 Million acquisition of Assertio Holdings, reflecting ongoing consolidation activity among mid-size pharmaceutical companies seeking to expand their commercial portfolios and manufacturing capabilities.
• November 2025 — Merck and Co. entered a USD 700 Million research funding agreement with Blackstone Life Sciences to develop a cancer therapy, demonstrating the scale of private capital deployment into biopharmaceutical R&D programs that will generate future cell culture manufacturing demand.
• July 2025 — Sartorius Stedim Biotech partnered with Sensible Biotechnologies to scale a cell-based mRNA manufacturing platform, expanding Sartorius' platform presence into the emerging cell-based mRNA production modality and securing early positioning in a new cell culture application category.
• April 2025 — Sartorius and Mabion announced a strategic cooperation to advance biopharmaceutical development, combining Sartorius' bioprocess technology platform with Mabion's biologics development expertise to accelerate cell culture process development for biosimilar and novel biologic programs.
• June 2025 — Biocon raised Rs 4,500 crore through a Qualified Institutional Placement, providing capital to support the expansion of its biologics manufacturing operations and biosimilar pipeline development.
• May 2025 — Avammune Therapeutics secured USD 12 Million in Series A funding to advance cancer therapies, representing early-stage capital formation for a biologic drug developer whose programs will require cell culture-based manufacturing as they progress through clinical development.
• November 2024 — Roche agreed to acquire Poseida Therapeutics in a deal worth up to USD 1.5 Billion, strengthening Roche's cell and gene therapy portfolio and expanding its requirement for specialized cell culture manufacturing capabilities for advanced therapy programs.
• October 2024 — SK bioscience completed acquisition of a controlling stake in IDT Biologika, combining SK bioscience's biologics manufacturing capabilities with IDT Biologika's vaccine and CDMO expertise to create an expanded cell culture manufacturing platform across Asia and Europe.
• October 2024 — Merck completed the acquisition of investigational B-cell depletion therapy CN201 from Curon Biopharmaceutical, adding a cell culture-manufactured biologic candidate to its immunology pipeline and creating a new commercial manufacturing program that will require dedicated cell culture production capacity.
• July 2024 — Eli Lilly announced the acquisition of Morphic Holding to strengthen its inflammatory bowel disease portfolio, adding an integrin inhibitor program that will require cell culture-based manufacturing scale-up as it advances toward commercial launch.
  

Report Characteristics
Market Value (2025)	USD 13.28 Billion
Forecast Revenue (2035)	USD 62.37 Billion
CAGR (2026–2035)	16.9%
Base Year for Estimation	2025
Historic Period	2020–2024
Forecast Period	2026–2035
Report Coverage	Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments
Segments Covered	By Product (Consumables, Equipment), By Application (Biopharmaceutical Production, Monoclonal Antibodies Production, Vaccines Production, Cell and Gene Therapy, Drug Screening and Development, Tissue Engineering and Regenerative Medicine, Diagnostics), By Type (Monoclonal Antibodies, Vaccines, Other Therapeutic Proteins), By End-User (Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Laboratories, Research and Academic Institutes, CROs and CMOs), By Technology (2D Cell Culture, 3D Cell Culture, Perfusion Cell Culture, High-Throughput Cell Culture), By Raw Material (Media, Sera, Reagents, Vessels, Growth Factors and Cytokines, Buffers and Chemicals), By 3D Cell Culture Technology (Scaffold-based, Scaffold-free, Microfluidics, Bioprinting), By Single-Use Systems (Single-Use Bioreactors, Single-Use Filtration Systems, Single-Use Storage Systems, Tubing and Connectors, Single-Use Sensors and Probes), By Cell Line Type (Primary Cells, Immortalized Cell Lines, Stem Cells, Genetically Engineered Cell Lines)
Regional Analysis	North America (US and Canada), Europe (Germany, France, The UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, South Korea, India, Australia, and Rest of APAC), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East & Africa (GCC, South Africa, and Rest of MEA)
Competitive Landscape	Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius AG, Merck KGaA, Corning Incorporated, FUJIFILM Holdings Corporation, BD, GE Healthcare (Cytiva), Lonza Group Ltd., Caisson Labs, Solida Biotech GmbH, Bio-Techne Corp, PromoCell GmbH, Avantor Inc
Customization Scope	Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
Purchase Options	We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)